HSBC yesterday afternoon downgraded AbbVie (ABBV) to Hold from Buy with a price target of $225, up from $210. AbbVie remains a solid execution story but the shares offer limited upside from current levels, the analyst told investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie downgraded to Hold from Buy at HSBC
- Nike reports Q1 beat, U.S. takes 5% stake in Lithium Americas: Morning Buzz
- Climb Bio appoints Altschuller as Chief Financial Officer
- Bristol Myers, Takeda, Astex to contribute data for AI tool, Reuters says
- AbbVie begins construction on $70M expansion to bioresearch center in MA